BioLineRx Ltd.
Biopharma firm developing and commercializing therapies for cancer and rare diseases.
BLRX | TA
Overview
Corporate Details
- ISIN(s):
- US09071M2052 (+1 more)
- LEI:
- 529900AKIOSC15Y63R18
- Country:
- Israel
- Address:
- Modi'in Technology Park, 2 HaMa'ayan Street, 7177871 Modi'in
- Website:
- https://www.biolinerx.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
BioLineRx Ltd. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapeutics for patients with specific cancers and rare diseases. The company leverages its comprehensive expertise to advance novel drug candidates through the entire development lifecycle, from preclinical research and clinical trials to regulatory approval and marketing. BioLineRx manages its own pipeline of therapies and also serves as a strategic partner for other drug developers, helping to advance promising early-stage compounds. The company's goal is to deliver meaningful and life-changing treatments that address significant unmet medical needs.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-17 15:01 |
Regulatory News Service
BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Coverin…
|
Hebrew (modern) | 201.5 KB | ||
| 2025-11-17 15:01 |
Foreign Filer Report
BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Coverin…
|
English | 36.6 KB | ||
| 2025-09-29 16:02 |
Foreign Filer Report
BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a …
|
English | 368.6 KB | ||
| 2025-09-29 16:02 |
Foreign Filer Report
BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a …
|
English | 36.6 KB | ||
| 2025-08-14 16:01 |
Earnings Release
Second Quarter 2025 Financial Results and Provides Corporate Update
|
English | 375.7 KB | ||
| 2025-08-14 16:01 |
Foreign Filer Report
Second Quarter 2025 Financial Results and Provides Corporate Update
|
English | 36.5 KB | ||
| 2025-07-26 23:19 |
Prospectus
Immediate Report
|
English | 397.4 KB | ||
| 2025-07-26 23:19 |
Prospectus
Immediate Report
|
English | 36.3 KB | ||
| 2025-07-01 01:25 |
Foreign Filer Report
Immediate Report
|
English | 127.3 KB | ||
| 2025-07-01 01:25 |
Foreign Filer Report
Immediate Report
|
English | 36.5 KB | ||
| 2025-05-30 17:23 |
Foreign Filer Report
New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-L…
|
English | 153.1 KB | ||
| 2025-05-30 17:23 |
Foreign Filer Report
New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-L…
|
English | 36.4 KB | ||
| 2025-05-27 16:01 |
Foreign Filer Report
BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate U…
|
English | 430.8 KB | ||
| 2025-05-27 16:01 |
Foreign Filer Report
BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate U…
|
English | 36.4 KB | ||
| 2025-05-24 23:14 |
Proxy Solicitation & Information Statement
Immediate Report of Meeting to be held on June 29,2025,proxy statement
|
English | 160.1 KB |
Automate Your Workflow. Get a real-time feed of all BioLineRx Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BioLineRx Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BioLineRx Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
